***TASK*** the task is to summarize an input biomedical literature in six sentences 
    ***INPUT*** the input is a biomedical literature 
    ***OUTPUT*** the output is the summary of an input biomedical literature in six sentences 
    ***DOCUMENTATION*** 
    ***EXAMPLES*** 
    Input: Twenty-one cystic fibrosis patients under 3 years of age were enrolled in an open multicenter study to assess the feasibility of the study design and to compare selected pharmacologic features of cephalexin or dicloxacillin administered orally for 2 months . Patient tolerance and compliance were significantly less for dicloxacillin ( p less than .01 and p less than .001 , respectively ) . Superficial C and ida infections were more common in the cephalexin group ( p = 0.02 ) , however increased stool frequency and nonspecific diaper rashes were more prevalent in patients receiving dicloxacillin ( p less than .05 ) . Staphylococcus aureus was isolated from respiratory secretions after 2 months from two dicloxacillin and no cephalexin patients . Areas under the curve and peak serum concentrations were higher for cephalexin ( p less than .05 and p = .02 ) , but antistaphylococcal activity in serum was higher for dicloxacillin ( p less than .05 ) due to a lower mean MIC compared to cephalexin . Deep pharyngeal plus routine throat culture yielded more pathogens than either method alone . Express mail and central processing of respiratory specimens was efficient for most organisms , however there was some loss of Streptococcus pneumoniae and Haemophilus influenzae .  Cephalexin was associated with better patient acceptance and compliance despite higher rates of superficial fungal infections as compared to dicloxacillin . Cephalexin , routine bacteriologic throat swabs processed locally or central ly , mail-in urine compliance assessment and a multicenter design are feasible components for a long-term prospect i ve evaluation of antibiotic prophylaxis in patients with cystic fibrosis This paper attempts to explain why systematic review s of r and omized controlled trials , based on as high a proportion as possible of the relevant studies , are so important in generating reliable information for evidence -based decision making within health care . The preparation , maintenance and dissemination of such review s is the challenge which has been taken up by the Cochrane Collaboration . The first phase of data collection is the identification of relevant studies . Currently , bibliographic data bases are inadequate for this task . MEDLINE search es identify on average only about half of the relevant studies , and until 1994 there were no suitable indexing terms in EMBASE to identify r and omized controlled trials . Co-operation between the Cochrane Collaboration and both the National Library of Medicine and Elsevier , however , is already transforming this situation . From January 1994 a new indexing term has been added to EMBASE to help identify r and omized controlled trials . From January 1995 a new indexing term will be added to MEDLINE to help identify controlled trials where the method of allocation to treatment or control can not be described with certainty as being r and omized . Also from January 1995 an additional 20,000 reports will be identifiable as r and omized controlled trials in MEDLINE . Progress during the first 2 years of the Cochrane Collaboration has been encouraging , but much remains to be done if users of health services are to benefit from the evidence -based health care which they deserve All newborn infants in East Anglia are screened for cystic fibrosis by blood immunoreactive trypsin assay at 7 days . Thirty eight infants with cystic fibrosis were r and omised to treatment with either continuous oral flucloxacillin 250 mg/day ( group P , n = 18 ) or with episodic antimicrobials as clinical ly indicated ( group E , n = 20 ) . Their progress was monitored from diagnosis to 24 months by a nurse coordinator who visited all infants regularly , at home and in hospital , to collect anthropometric , dietary , clinical , and microbiological data . Mean ( range ) age of confirmation of diagnosis was 5.7 weeks ( 1 - 14 weeks ) . There was no significant difference in birth weight , genotype , immunoreactive trypsin concentration , neonatal history , symptoms at diagnosis , pancreatic enzyme supplementation , or parental smoking history between the groups . Infants in group E had more frequent cough and a greater number of Staphylococcus aureus isolates than infants in group P. More infants of group E were admitted to hospital , had higher admission rates during the second year ( 19 v 5 ) , for longer periods ( 6.4 v 2.2 days ) , despite receiving more than double the number of courses of antibiotics than group P infants ( in addition to flucloxacillin ) . Continuous prophylactic flucloxacillin from early diagnosis of cystic fibrosis is associated with improved clinical progress during the first two years of life [ N PATIENTS with cystic fibrosis , the progression of pulmonary disease following Staphylococcus aureus colonization and the improvement after its eradication suggest that S. aureus may be more important than Pseudomonas aeruginosa and Haemophilus influenzae as primary pathogens . 1'~ The favorable results in CF patients using continuous antistaphylococcal therapy with cloxacillin 3 support this idea . Moreover , S. aureus produces microabscesses of the lung 4 and remains in a CF patient 's sputum despite prolonged administration of antibiotics ? Patients with cystic fibrosis developed precipitating antibodies against S. aureus more frequently than against other sputum pathogens . We therefore studied 29 CF patients receiving prophylactic pulmonary care 6 at the University of Minnesota Hospitals who gave informed consent for treatment of staphylococcal infections with clindamycin 
    Output:
    
Sputum clearance of S aureus was more frequently achieved than any other beneficial outcome .
A beneficial effect on pulmonary function was rarely measured or observed .
Antistaphylococcal treatment achieves sputum clearance of S aureus in patients with cystic fibrosis .
Prophylactic antistaphylococcal treatment in young children with cystic fibrosis is likely to be of clinical benefit .
It remains to be determined whether the use of " prophylactic " versus " intermittent " antistaphylococcal therapy in cystic fibrosis is associated with improved lung function and /or chest radiographic scores , an increase in bacterial resistance , or earlier acquisition of Pseudomonas aeruginosa .